Pluristem Therapeutic is a bio-therapeutics Company dedicated to the commercialization of non-personalized cell therapy products for the treatment of several severe degenerative ischemic and autoimmune disorders.


Updates from The Motley Fool

Latest updates on Pluristem Therapeutics from Fool.com.
This Week in Biotech: Part 2

Consider this the continuation of what's been an incredibly busy week for biotech companies in te...

The Stocks Wall Street Loves

Despite all of Wall Street's conflict and contention, a fortunate few companies enjoy unanimous s...

One Stem Cell Stock to Avoid

Each week, Motley Fool editors cull a top stock idea from the pitches made on CAPS, the Motley Fo...

Hidden Stocks for High Returns

Like the song says, investors are looking for stocks to love in all the wrong places . They'll ...



Stock Performance

View Interactive PSTI Charts
Sponsored by

Key Data Points

Primary metrics and data points about Pluristem Therapeutics.
Current Price: $1.54
Prev Close: $1.47
Open: $1.53
Bid: $1.53
Ask: $1.54
Day's Range: $1.52 - $1.56
52wk Range: $0.71 - $1.85
Volume: 120,160
Avg Vol 130,749
Market Cap: $122M
P/E (ttm): -4.90
EPS (ttm): ($0.30)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Pluristem Therapeutics.
CAPS Rating 1 out of 5
 
47 Outperform
26 Underperform
CAPS All Stars
 
2 Outperform
18 Underperform

How do you think Pluristem Therapeutics will perform against the market?



You pick for Pluristem Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Zami Aberman, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Pluristem Therapeutics.

Pluristem Therapeutic is a bio-therapeutics Company dedicated to the commercialization of non-personalized cell therapy products for the treatment of several severe degenerative ischemic and autoimmune disorders.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers